Trial Profile
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2020
Price :
$35
*
At a glance
- Drugs Bimatoprost/brimonidine/timolol (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Allergan
- 20 Feb 2020 Primary endpoint (Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) has been met published in the Clinical Therapeutics
- 20 Feb 2020 Results assessing the safety and IOP-lowering efficacy of TFC (compared with DFC) in Brazilian patients with POAG or OHT published in the Clinical Therapeutics
- 03 Dec 2015 New trial record